Yahoo Finance These 4 Healthcare Stocks Are Heating Up
CORAL GABLES, FL / ACCESSWIRE / December 28, 2018 / The healthcare industry has shown tremendous growth over the last few months, as experts and professionals in the field have worked on developing technologies to improve the quality of care for patients on a global scale. From data-based approaches and analysis consumer demands/needs, advancements in the sector may catalyze potential opportunities for those looking to healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Akers Biosciences Inc (AKER), CASI Pharmaceuticals Inc (CASI), and Rite Aid Corporation (RAD) represent 4 healthcare companies innovating towards the future.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced, earlier this month that as part of its overarching strategy to cover major verticals associated with primary care, it had signed into a binding Letter of Intent (LOI) agreement to acquire a Vancouver-based pharmacy. According to reports regarding the acquisition, the Company expects the deal to close in our about Q1-19. Presently, the Company supports an ecosystem of over 100,000 active patients and has plans to rapidly increase their member base both domestically, as well as internationally.
Additionally, Premier Health Group (OTC:PHGRF) (CSE:PHGI) has made it a priority to partner with telemedical experts and providers to strengthen its immensely successfully HealthVue app, which allows patients to access primary care from wherever they may be in the world through the use of a smartphone application.
"We are excited for this opportunity to acquire our first pharmacy, and thereafter being able to prepare and deliver prescription and non-prescription pharmaceuticals and other health products to patients. In doing so, the pharmacist will play an integral role in our team-based patient centric model," said Dr. Essam Hamza, CEO of Premier. "Premier has engaged with patients, pharmacies and technology providers to not only introduce pharmacy services as a component of our comprehensive telemedicine app, but also to explore and implement efficiencies in fill and fulfillment."
For More Information On Premier Health Group, Click Here
Akers Biosciences, Inc (AKER) enjoyed positive gains in early afternoon trading on Friday as its shares shot up 8.25% to $1.08 per share. Back in March, the Company, known for its development of rapid health information technologies, announced that it had entered into a three-year National Distribution Agreement with Diagnostica Stago, inc for the sale of the Company's flagship rapid test for Heparin-induced thrombocytopenia across the U.S.
According to a press release issued at the time, John J. Gormally, the Company's chief executive officer commented, ''The addition of Stago to our growing and distinguished distributor network is a significant milestone in the commercialization of PIFA PLUSS PF4™. Stago is a recognized leader in the field of hemostasis and has a very large and established customer base to which to market our product. Through Stago, Akers Bio will gain access to a dedicated and specialized sales team who are focused exclusively on buyers of hemostasis-related products. Akers Bio is excited about the potential for near-term US sales growth through this new, additional and specialized channel to market.''
For More Information On Akers Biosciences, Inc, Click Here
CASI Pharmaceuticals Inc (CASI), a biopharmaceutical company dedicated to developing high-quality products and therapeutics to the global health market, announced earlier this month that it had received National Medical Products Administration approval of Melphalan Hydrochloride For Injection.
CASI Pharmaceuticals Executive Chairman Wei-Wu He, Ph.D., commented, ''NMPA approval of Melphalan Hydrochloride For Injection (EVOMELA®) is encouraging news for patients in China with multiple myeloma as there is no commercially available melphalan formulation in the country. EVOMELA's approval, therefore, addresses a significant unmet medical need. In addition, EVOMELA®‘s proprietary formulation of melphalan, a first-line therapy for multiple myeloma patients, offers considerable clinical advantages as it does not contain propylene glycol, which may cause side effects, it has long stability when reconstituted for infusion, and is the only intravenous melphalan product approved for use in the high-dose conditioning indication in pre-transplant therapy.''
For More Information on CASI Pharmaceuticals, Inc, Click Here
Rite Aid Corporation (RAD) announced last week that it had entered into a new senior secured credit agreement, consisting of a $2.7 billion senior secured asset-based revolving credit facility and a $450 million ''first in, last out'' senior secured term loan facility.
According to the press release issued at the time of the announcement, Merrill Lynch, Pierce, Fenner & Smith Incorporated, Wells Fargo Bank, National Association, Citigroup Global Markets Inc., BMO Harris Bank, N.A., Capital One, National Association, Fifth Third Bank, ING Capital LLC, MUFG Union Bank, N.A., PNC Capital Markets LLC and SunTrust Robinson Humphrey, Inc., acted as joint lead arrangers and joint book runners for the new facilities. Bank of America, N.A. is acting as administrative agent and collateral agent under the new credit facilities.
For More Information On Rite Aid Corporation, Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 -4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid ''500,000'' shares of restricted common shares. We were paid an additional $100,000 (CASH) for continued coverage. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
CONTACT:
SOURCE: Stock Price
